#Germany #Munich #Atrial Fibrillation #Sky Labs #CART Monitor

Introduction

The ESC Congress 2026 held in Munich has become a platform for significant advancements in healthcare technology, particularly with the unveiling of the CART blood pressure monitor by Sky Labs, led by CEO Jack ByungHwan Lee. This innovative device is tailored for patients suffering from atrial fibrillation (AF) and heart failure, as clinical studies reveal promising results underscoring its effectiveness in continuous blood pressure monitoring.

Innovative Features of the CART Monitor

The CART monitor, designed in a ring format, employs cutting-edge PPG sensors and AI-driven deep learning. This technology allows for cuffless, 24-hour blood pressure monitoring, a crucial advancement for patients whose conditions typically hinder traditional blood pressure measurement methods. The monitor enables consistent 24-hour assessment, offering unparalleled utility for patients whose pulse rates fluctuate significantly, making conventional monitoring ineffective.

Clinical Outcomes Presented at ESC 2026

At the ESC Congress, leading cardiologists presented compelling clinical outcomes showcasing the CART device's capabilities. Among those was Professor Ki-Hong Lee from Chonnam National University Hospital, who advocated for the monitor's efficacy in AF patients, noting a data retrieval rate of approximately 80%. He stressed that the CART system facilitates the continuous capture of nightly dipping patterns, which is vital for understanding individual patient responses.
Professor In-Cheol Kim from Keimyung University Dongsan Hospital also highlighted the monitor’s performance in patients with severe heart failure, demonstrating a remarkable correlation between CART readings and conventional ambulatory 24-hour blood pressure measurement (ABPM). The findings met the European Society of Hypertension (ESH) criteria, showcasing the CART's potential for personalized therapy in heart failure management.

Broad Applications and Future Directions

The implications of the CART monitor extend beyond just AF and heart failure; it is also positioned as a valuable tool in the management of sleep apnea. Analysis presented by Professor Jong-Chan Youn depicted a clear increase in blood pressure following respiratory interruptions in patients, emphasizing the monitor's potential to provide critical real-time insights.
Sky Labs is rapidly establishing itself as a pioneer in cuffless blood pressure technology. Their adherence to stringent ESH validation criteria positions them as leaders in the global market. As noted by other experts like Professor Seok-Min Kang, the CART device fulfills necessary benchmarks for accurate blood pressure monitoring without cuffs.

Continued Expansion and Market Integration

With over 300,000 prescriptions written and ongoing use within more than 2,000 medical institutions in South Korea, the CART monitor is well on its way to becoming a staple in chronic disease management. The recent inclusion in the 2026 clinical guidelines by the Korean Society of Hypertension marks a significant milestone, reinforcing the device's credibility within the medical community.
Jack ByungHwan Lee enthused about the potential of CART, indicating that the company will expedite its expansion efforts into Europe and other international markets. The foundation laid through clinical evidence and growing adoption presents a unique opportunity to enhance patient care globally.

Conclusion

In summary, the CART blood pressure monitor by Sky Labs is setting a new standard in patient management for atrial fibrillation and heart failure. The innovative technology, robust clinical validation, and the potential for integration into broad healthcare practices highlight its transformative impact on monitoring cardiovascular health. As Sky Labs continues its global push, the future of blood pressure monitoring looks promisingly advanced, shifting towards more patient-centered approaches.